(19)
(11) EP 2 010 570 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.01.2015 Bulletin 2015/04

(45) Mention of the grant of the patent:
19.11.2014 Bulletin 2014/47

(21) Application number: 07732356.6

(22) Date of filing: 10.04.2007
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61K 39/395(2006.01)
A61P 35/00(2006.01)
C12N 9/54(2006.01)
 C07K 16/40(2006.01)
A61K 31/00(2006.01)
G01N 33/573(2006.01)
(86) International application number:
PCT/GB2007/001312
(87) International publication number:
WO 2007/128987 (15.11.2007 Gazette 2007/46)

(54)

THERAPY AGAINST CATHEPSIN S

THERAPIE GEGEN CATHEPSIN S

THERAPIE VERS CATHEPSIN S

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 10.04.2006 GB 0607158
12.10.2006 GB 0620255

(43) Date of publication of application:
07.01.2009 Bulletin 2009/02

(73) Proprietor: Fusion Antibodies Limited
Belfast, BT17 0QL (GB)

(72) Inventors:
  • OLWILL, Shane
    Belfast BT1 2WD (GB)
  • SCOTT, Christopher
    Belfast BT1 2WD (GB)
  • GORMLEY, Julie
    Belfast BT1 2WD (GB)
  • THOMAS, Jaquin
    Belfast BT1 2WD (GB)
  • BURDEN, Roberta
    Belfast BT1 2WD (GB)
  • MCMEEL, Darragh
    Belfast BT1 2WD (GB)
  • JOHNSTON, James
    Belfast BT1 2WD (GB)

(74) Representative: Main, Malcolm Charles 
Murgitroyd & Company Scotland House 165-169 Scotland Street
Glasgow G5 8PL
Glasgow G5 8PL (GB)


(56) References cited: : 
WO-A-2006/109045
   
  • JOYCE JOHANNA A ET AL: "Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis" CANCER CELL, XX, US, vol. 5, no. 5, May 2004 (2004-05), pages 443-453, XP009086749 ISSN: 1535-6108
  • KOS J ET AL: "Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis." BRITISH JOURNAL OF CANCER 19 OCT 2001, vol. 85, no. 8, 19 October 2001 (2001-10-19), pages 1193-1200, XP002455887 ISSN: 0007-0920 cited in the application
  • BERDOWSKA I: "Cysteine proteases as disease markers" CLINICA CHIMICA ACTA, AMSTERDAM, NL, vol. 342, no. 1-2, April 2004 (2004-04), pages 41-69, XP008084692 ISSN: 0009-8981
  • FALGUEYRET J-P ET AL: "An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 335, no. 2, 15 December 2004 (2004-12-15), pages 218-227, XP004642079 ISSN: 0003-2697
  • GERBER DAVID E: "Targeted therapies: a new generation of cancer treatments.", AMERICAN FAMILY PHYSICIAN 1 FEB 2008, vol. 77, no. 3, 1 February 2008 (2008-02-01), pages 311-319, ISSN: 0002-838X
  • RODRIGUEZ J ET AL: "Combining chemotherapy and targeted therapies in metastatic colorectal cancer.", WORLD JOURNAL OF GASTROENTEROLOGY : WJG 28 NOV 2007, vol. 13, no. 44, 28 November 2007 (2007-11-28), pages 5867-5876, ISSN: 1007-9327
  • BEN-ARI ELIA T: "Dual purpose: some cancer therapies used to treat autoimmune diseases.", JOURNAL OF THE NATIONAL CANCER INSTITUTE 21 APR 2004 LNKD- PUBMED:15100330, vol. 96, no. 8, 21 April 2004 (2004-04-21) , pages 577-579, ISSN: 1460-2105
  • GOODWIN D A: "Pharmacokinetics and antibodies.", JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE AUG 1987 LNKD- PUBMED:3612296, vol. 28, no. 8, August 1987 (1987-08), pages 1358-1362, ISSN: 0161-5505
  • NG EUGENE W M ET AL: "TARGETING ANGIOGENESIS, THE UNDERLYING DISORDER IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION", CANADIAN JOURNAL OF OPHTHALMOLOGY, CANADIAN OPHTHALMOLOGICAL SOCIETY, CA, vol. 40, no. 3, 1 June 2005 (2005-06-01), pages 352-368, XP009078843, ISSN: 0008-4182
  • BUCHSBAUM D J: "EXPERIMENTAL APPROACHES TO INCREASE RADIOLABELED ANTIBODY LOCALIZATION IN TUMORS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 55, 1 December 1995 (1995-12-01), pages 5729S-5732S, XP000619269, ISSN: 0008-5472
  • GOLDENBERG DAVID M ET AL: "Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 24, no. 5, 10 February 2006 (2006-02-10), pages 823-834, XP008126357, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.03.8471 [retrieved on 2005-12-27]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).